- Home
- RLYB
RLYB
Rallybio Corporation
as 11-21-2024 4:00pm EST
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 42.3M | IPO Year: | 2021 |
| Target Price: | $8.10 | AVG Volume (30 days): | 70.0K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $3.46 | Next Earning Date: | 11-07-2024 |
| Revenue: | $598,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -74.96% |
Latest Rallybio Corporation News
RLYB Breaking Stock News: Dive into RLYB Ticker-Specific Updates for Smart Investing
Business Wire
17 hours ago
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Simply Wall St.
9 days ago
3 US Penny Stocks With Market Caps Over $40M To Consider
Business Wire
15 days ago
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
Pharma Voice
17 days ago
Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech
MT Newswires
24 days ago
Rallybio Gets Clearance for Phase 2 Alloimunization Study in Europe, UK
Business Wire
24 days ago
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
Business Wire
2 months ago
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
Business Wire
2 months ago
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
Compare RLYB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLYB Rallybio Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.